

East Anglia's Children's Hospices Buccal opioid use for pain and dyspnoea for children with palliative care needs during end of life care Linda Maynard, Nurse Consultant¹ Cheryl Norman, Matron¹ Debbi Lynn, Matron I CHARITIES FORUM Harry Taylor, Matron¹ Pat Sartori, Consultant in Paediatric Palliative & Supportive Care²

> ¹East Anglia's Children's Hospices (EACH) Cambridge, UK ²Cambridge University Hospitals NHS Foundation Trust





Introduction

EACH provides palliative and end of life care to children and young people with life threatening and life limiting conditions and their families living in Cambridgeshire, Norfolk, Suffolk and North East/West Essex in the UK.



Findings

- Total children and young people case notes reviewed n=26
- Opioid prescribed (Diamorphine Hydrochloride, Oxycodone Hydrochloride, Fentanyl) n=21
- Buccal opioid administered n=17





- antly rural with pockets of urban areas

- General hospitals with paediatric wards x10
- Children's community nursing teams x7

Figure I: EACH catchment

This poster reports on a retrospective study which explored buccal administration of opioids and aimed to elicit effectiveness, advantages and disadvantages for breakthrough pain and dyspnoea in symptom control during end of life care. Implications for nursing practice were identified.

Background

The buccal mucosa is an effective route for medication administration because it:

- Avoids drug degradation in stomach and first pass metabolism
- Enables rapid absorption
- Is fast acting
- Is minimally invasive
- Has increased bioavailability

When caring for children, especially in the home environment, it is most convenient when prescribed and prepared in advance.

IN THE PREFICAL PRODUCT Singlyao (gums) guccal, Rogioni ww.sciencedirect.com/science/article/pii/

- Oxycodone Hydrochloride n=2
- Diamorphine Hydrochloride n=15 _____

Buccal administration was effective for all children except 3 (17.6%)

- One responded to use of a buccal anxiolytic (Midazolam);
- One received IV bolus of opioid with effect; and
- One had continuous subcutaneous infusion dose increase as buccal administration was ineffective in last few hours of life.

Advantages & Disadvantages

Figure 6: Advantages & disadvantages of buccal route for effective breakthrough pain and dyspnoea

Advantages	Disadvantages
Fast acting	Unpalatable
Quick absorption	Storage in home/hospital
Relatively painless	• Wastage
Easy to administer	Drawing up small doses
Non-invasive	Benefit reduced if dose accidentally swallowed
 Parents empowered to give 	(salivary washout)
Low cost	
Can be used in unconscious patient	

Recommendations for Nursing Practice




Figure 5: Children's symptoms treated with buccal opioid

Patients & Method

A retrospective case note review of children and young people receiving end of life care at East Anglia's Children's Hospices over a 12 month period in 2017.

Patient demographics

- Children's care records reviewed n=26
- 54% female, 46% male
- Age range 8 days to 17 years




Figure 2: Place of death

Diagnoses

- 38% cancer
- 23% neurodegenerative conditions e.g. Metachromatic Leukodystrophy, Spinocerebellar Atrophy
- 39% other conditions such as Menkes disease, Nephrotic Syndrome
- 2 children were transferred from PICU / NICU for compassionate extubation.

Buccal route administration of opioids is a safe and effective medicines administration strategy. It requires organisational policy and procedures to guide practice.

An individual risk assessment of the preferred care environment for safe storage and disposal of buccal medication is essential.

Staff need training and to be assessed competent to prepare and administer buccal medication and be able to teach parents to give safely.

Accurate recording of effectiveness using appropriate pain/dyspnoea assessment tools is an integral part of the nursing care process.




Figure 7: Organisational policy

Procedure

- Prescribe opioid and water for injection for buccal use
- Risk assess safe storage when using in family home
- Cap and label each syringe with drug name, dose, date and nurse signature
- When made in advance store in a labelled, lidded box and keep refrigerated
- Discard at end of each shift in hospice
- May prepare and keep for up to seven days for parent administration in the home
- Provide a record sheet for parents to document administration
- When administering first dose give in 2-3 aliquots over 20 minutes monitoring effect.



Assessment Tools

Tools were used as standard practice to measure / record level of effectiveness.




Figure 3: EACH pain assessment tools




Figure 4: EACH shortness of breath scale





Figure 8: Preparation

References

- Lam, J.K., Xu, Y., Worsley, A. and Wong, I.C. (2014) Oral transmucosal drug delivery for pediatric use. Advanced drug delivery reviews, 73, pp.50-62.
- Raol S., Song Y., Peddie F., Evans A. (2011) Particle Size reduction to the nanometer range: a promising approach to improve buccal absorption of poorly water soluble drugs. International Journal of Nanomedicine. 6 p. 1245-1251 [Online] Available from https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131191/pdf/ijn-6-1245.pdf
- Simon S.M., Schwartzberg L.S.(2014) A review of rapid-onset opioids for breakthrough pain in patients with cancer. Journal of Opioid Management 10(3) June p.207-215

For further information please contact: Cheryl Norman, Cheryl.Norman@each.org.uk East Anglia's Children's Hospices (EACH), Church Lane, Milton, Cambridge, CB24 6AB Visit us at: <u>www.each.org.uk</u> EACH is a Registered Charity: 1069284



